Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  AbbVie    ABBV

ABBVIE (ABBV)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

AbbVie : adds biologic production capability to Singapore facility

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 12:12pm CET

The plant is the 13th site within the companys global manufacturing network which spans across the US, Europe and Puerto Rico, and is the only one of its kind within the network with the capability to produce both biologics and APIs. AbbVie employs around 400 workers in Singapore, around 250 of which serve at the manufacturing plant.

Singapores Minister for Trade and Industry, S Iswaran, was present at the opening ceremony, where he said the facility expansion came at an opportune moment to meet the increasing demands of ageing populations and technological advancement.

"While these shifts will disrupt existing business models, they also present significant new opportunities," he said.

According to Iswaran, the countrys government is committed to investing S$4 billion in health and biomedical sciences in addition to a further S$3.2 billion in advanced manufacturing and engineering as part of the Research Innovation and Enterprise (RIE) 2020 plan, a programme jointly developed by Workforce Singapore and the Singapore Economic Development Board.

"A strategic goal of RIE 2020 is to strengthen linkages between public research performers and private enterprises to create greater value from our investments in R&D," Iswaran noted.

Over 350 people have benefitted from the programme since its inception in 2014.

(c) 2003-2017 SudanTribune - All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABBVIE
12/15 ABBVIE : A new role for Bcl-XL in fibrosis
12/15 Wall Street falls as investors fret about tax bill passage
12/14 ABBVIE : Recent Data from A.J. Epstein and Co-Authors Highlight Findings in Endo..
12/14 ABBVIE : New Molecular Pharmaceutics Findings from AbbVie Discussed (Impact of P..
12/14 ABBVIE : IMBRUVICA Data Provide Insights Into Its Potential Treatment Benefits
12/14 ABBVIE : Announces Phase 3 Study of VENCLEXTA VENCLYXTO in Combination with Ritu..
12/13 ABBVIE : Roche boast stellar PhIII leukemia data for a breakthrough combo with b..
12/12 ABBVIE : IMBRUVICA Pooled Analysis Suggests Benefit in Progression-Free Survival..
12/12 ABBVIE : IMBRUVICA Patient-Reported Outcomes Data Detail Long-Term Improvement i..
12/12 ABBVIE : Announces Phase 3 Study of VENCLEXTA™/ VENCLYXTO™ (venetocl..
More news
News from SeekingAlpha
12/15 MY JOURNEY TO FINANCIAL INDEPENDENCE : 86-Stock November Portfolio Update - Buyi..
12/14 More Positives For Roche, The Core Biotech For The Long Run
12/14 BIOTECH ANALYSIS CENTRAL PHARMA NEWS : AbbVie And Roche Stellar Data, Aduro Pull..
12/13 ARGENX : This ASH Winner Has Further Upside Ahead
12/13 3 THINGS IN BIOTECH YOU SHOULD LEARN : December 13, 2017
Financials ($)
Sales 2017 27 998 M
EBIT 2017 11 955 M
Net income 2017 7 316 M
Debt 2017 26 790 M
Yield 2017 2,67%
P/E ratio 2017 21,01
P/E ratio 2018 16,57
EV / Sales 2017 6,51x
EV / Sales 2018 5,76x
Capitalization 155 B
Chart ABBVIE
Duration : Period :
AbbVie Technical Analysis Chart | ABBV | US00287Y1091 | 4-Traders
Technical analysis trends ABBVIE
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 100 $
Spread / Average Target 3,0%
EPS Revisions
Managers
NameTitle
Richard A. Gonzalez Chairman & Chief Executive Officer
Azita Saleki-Gerhardt Senior Vice President-Operations
William J. Chase Chief Financial Officer & Executive Vice President
Michael E. Severino Chief Scientific Officer & Executive VP
Robert J. Alpern Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBVIE53.78%155 345
MERCK KGAA-9.18%13 715
KYOWA HAKKO KIRIN CO LTD33.44%11 113
JAZZ PHARMACEUTICALS PLC24.28%8 123
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD38.39%5 786
CONVATEC GROUP-13.13%5 322